Heloisa Soares examined the unmet need in managing neuroendocrine tumors (NETs), the impact of current phase 3 trials on the management of well-differentiated NETs, the role of molecular profiling in neuroendocrine neoplasm management, and how future guidelines for gastroenteropancreatic NETs may change with the recent theranostics developments.

Maribel del Olmo reviewed the advantages and disadvantages of somatostatin analogs for patients with somatostatin receptor-positive neuroendocrine tumors, the evolving treatment landscape for these patients, the necessary steps if a non-functional NET becomes functional during radiopharmaceutical therapy, and the promising advancements in innovative radiopharmaceuticals.

Watch Damian Wild discuss the role of nuclear medicine physicians in multidisciplinary oncology tumor boards, strategies for engaging oncologists in the theranostics-related management of their patients, and the future of dosimetry in clinical practice. He also shares valuable insights for young professionals exploring opportunities in theranostics.

In part two of this two-part video series, nuclear medicine physician Chiara Maria Grana and medical oncologist Jaume Capdevila share their key takeaways from ENETS 2025 directly from the ICE Kraków Congress Centre.

In part one of a two-part video series, nuclear medicine physician Chiara Maria Grana and medical oncologist Jaume Capdevila discussed the most exciting insights presented at the Annual Conference of the European Neuroendocrine Tumor Society e.V. (ENETS), which took place from March 5-7, 2025 at the ICE Kraków Congress Centre in Poland.

Andrea Frilling discusses the reasons why some patients with neuroendocrine tumors (NETs) are not eligible for curative surgical treatment, the current state of neoadjuvant and adjuvant therapies for NET patients, the available treatment options for NET patients who have liver metastasis, and the main highlight from ENETS 2024. 

Wouter de Herder explains the critical role of endocrinology in managing patients with neuroendocrine neoplasms, the principles of somatostatin analog therapy and identifies the groups of neuroendocrine tumor (NET) patients who benefit most from it, the recommended second-line treatment for patients with advanced, unresectable, or metastasized gastroentero-pancreatic NET after recurrence with somatostatin analogs, and the main highlights from ENETS 2024.

Julien Hadoux describes various ways to improve the early and accurate diagnosis and treatment of patients with neuroendocrine tumors (NETs), the present and future aspects of molecular profiling in the management of NETs, the use of radiopharmaceutical therapy (RPT) compared to other systemic targeted therapies in the treatment sequence of patients with NETs, and the main highlights from ENETS 2024. 

Paola Erba discusses the use of FDG PET/CT in conjunction with somatostatin receptor imaging for the initial staging of patients with neuroendocrine tumors, how the recent developments in theranostics have influenced guidelines and recommendations for treating neuroendocrine tumors (NETs), the challenges and needs for expanding access to radiopharmaceutical treatment (RPT), and the main highlights from the ENETS 2024.

Thor Halfdanarson talks about the multidisciplinary care approach to treating patients with neuroendocrine tumors (NETs), imaging techniques for initial staging, restaging and monitoring the effectiveness of treatment in NET patients, the variations in the treatment guidelines for NETs between Europe and the USA and the main takeaways from ENETS 2024. 

Prof. Grana provides an overview of the main issues and challenges currently facing PRRT and its role in managing NETs.

Prof. Capdevila shares his views on the potential impact of ongoing phase III studies on the guidelines for managing well-differentiated neuroendocrine tumors.

Professor Nagarajah guides us through the latest developments in PSMA-targeting radiopharmaceuticals and shares his views on the role of dosimetry in radionuclide therapy.

Discover how the recent advancements in theranostics have revolutionized nuclear medicine through Prof. Pubul Núñez's insightful explanation.